Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • Nelarabine Injection
  • Pipeline
    • SH-105
    • SH-110
    • SH-114
    • SH-201
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Uncategorised

Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection

May 16th 2023

Read More

CEO Sharon Cunningham met with Minister Robert Troy at Enterprise Ireland’s trade visit in Boston

March 7th 2022November 4th 2021

Read More

Team Shorla Oncology complete 100k in 30 days for Breast Cancer

March 7th 2022June 30th 2021

Read More

FDA filing acceptance and priority review received for SH-111

March 7th 2022April 23rd 2021

Read More

Shorla Oncology named Local Enterprise of the Year at The Irish Times Business Awards 2020

March 7th 2022September 3rd 2020

Read More

Shorla Oncology closes $8.3M Series A funding round

March 7th 2022June 6th 2020

Read More

Manufacture of first GMP batch of SH-111

March 7th 2022May 11th 2020

Read More

Worldwide Association of MBA’s Best Entrepreneurial Venture Award (Private Sector) 2020

April 15th 2021February 7th 2020

Read More

SodEXo Women Mean Business (WMB) Female Newcomer Award 2019

April 15th 2021October 20th 2019

Read More

Older posts
Page1 Page2

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

 

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP
PRIVACY POLICY
Company number: 618033
©SHORLA ONCOLOGY® 2022

© 2023 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • Nelarabine Injection
  • Pipeline
    • SH-105
    • SH-110
    • SH-114
    • SH-201
  • News
    • Company Updates
    • Media
  • Careers
  • Contact